ArticleBiomaterials research2026
Light-Curable Methacrylated Carboxymethyl Chitosan Hydrogel Incorporating Bone Morphogenic Protein-2-Immobilized Bioactive Glass for Spinal Bone Regeneration.
Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioactive glass (BG) has emerged as a promising material for bone tissue engineering due to its ability to release osteogenic ions and establish robust interfaces with living tissues, thereby contributing to spinal bone regeneration by facilitating osteointegration and structural stability. Despite these advantageous properties, reconstructing spinal bone defects remains particularly challenging because BG is typically available in powder form, which lacks sufficient mechanical strength and is difficult to handle surgically, especially given the substantial mechanical demands of the spinal column. To overcome these limitations, we employed an injectable, light-curable methacrylated carboxymethyl chitosan (CMCSMA) hydrogel to enable minimally invasive delivery and precise defect filling. Furthermore, to complement BG's strong osteoconductive capacity with osteoinductive functionality, bone morphogenetic protein-2 (BMP-2) was immobilized onto BG particles (BG/BMP-2), creating a composite scaffold with dual biological activity. The BG/BMP-2/hydrogel system demonstrated sustained BMP-2 release, enhanced osteogenesis, and substantial new bone formation, underscoring the synergy between BG's bioactive ion release and hydroxyapatite-forming ability. The photocurable hydrogel matrix provided conformal adaptation to defect geometry, potentially improving surgical outcomes. Collectively, this composite represents a promising strategy for minimally invasive and mechanically resilient spinal bone regeneration.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.